Current perspectives on the diagnosis, assessment, and management of vasculitic neuropathy

References

• Said G, Lacroix C. Primary and secondary vasculitic neuropathy. J Neurol. 2005;252(6):633–641.
   PubMed Web of Science ®Google Scholar
• Collins MP, Dyck PJ, Gronseth GS, et al. Peripheral nerve society guideline on the classification, diagnosis, investigation, and immunosuppressive therapy of non-systemic vasculitic neuropathy: executive summary. J Peripher Nerv Syst. 2010;15(3):176–184.
   PubMed Web of Science ®Google Scholar
• Gwathmey KG, Burns TM, Collins MP, et al. Vasculitic neuropathies. Lancet Neurol. 2014;13(1):67–82.
   PubMed Web of Science ®Google Scholar
• Koike H, Nishi R, Ohyama K, et al. ANCA-associated vasculitic neuropathies: a review. Neurol Ther. 2022;11(1):21–38.
   PubMed Web of Science ®Google Scholar
• Jennette JC, Falk RJ, Bacon PA, et al. 2012 revised international chapel hill consensus conference nomenclature of vasculitides. Arthritis Rheum. 2013;65(1):1–11.
   PubMed Web of Science ®Google Scholar
• Dyck PJ, Benstead TJ, Conn DL, et al. Nonsystemic vasculitic neuropathy. Brain. 1987;110(Pt 4):843–853.
   PubMed Web of Science ®Google Scholar
• Sugiura M, Koike H, Iijima M, et al. Clinicopathologic features of nonsystemic vasculitic neuropathy and microscopic polyangiitis-associated neuropathy: a comparative study. J Neurol Sci. 2006;241(1–2):31–37.
   PubMed Web of Science ®Google Scholar
• Koike H, Sobue G. Clinicopathological features of neuropathy in anti-neutrophil cytoplasmic antibody-associated vasculitis. Clin Exp Nephrol. 2013;17(5):683–685.
   PubMed Web of Science ®Google Scholar
• Mathew L, Talbot K, Love S, et al. Treatment of vasculitic peripheral neuropathy: a retrospective analysis of outcome. Qjm. 2007;100(1):41–51.
   PubMed Web of Science ®Google Scholar
• Hawke SH, Davies L, Pamphlett R, et al. Vasculitic neuropathy. A clinical and pathological study. Brain. 1991;114((Pt5)):2175–2190.
   PubMedGoogle Scholar
• Shochet L, Holdsworth S, Kitching AR. Animal models of ANCA associated vasculitis. Front Immunol. 2020;11(525). DOI:10.3389/fimmu.2020.00525.
   PubMedGoogle Scholar
• Cuchacovich R. Immunopathogenesis of vasculitis. Curr Rheumatol Rep. 2002;4(1):9–17.
   PubMedGoogle Scholar
• Schreiber A, Xiao H, Jennette JC, et al. C5a receptor mediates neutrophil activation and ANCA-induced glomerulonephritis. J Am Soc Nephrol. 2009;20(2):289–298.
   PubMed Web of Science ®Google Scholar
• Radford DJ, Luu NT, Hewins P, et al. Antineutrophil cytoplasmic antibodies stabilize adhesion and promote migration of flowing neutrophils on endothelial cells. Arthritis Rheum. 2001;44(12):2851–2861.
   PubMedGoogle Scholar
• Falk RJ, Terrell RS, Charles LA, et al. Anti-neutrophil cytoplasmic autoantibodies induce neutrophils to degranulate and produce oxygen radicals in vitro. Proc Natl Acad Sci U S A. 1990;87(11):4115–4119.
   PubMed Web of Science ®Google Scholar
• Kimura H, Mii A, Shoji J, et al. Immunohistochemical detection of citrullinated histone H3-positive neutrophils is useful for identifying active glomerular and interstitial lesions in antineutrophil cytoplasmic antibody-associated vasculitis. Histopathology. 2021;78(4):520–531.
   PubMed Web of Science ®Google Scholar
• O’Sullivan KM, Holdsworth SR. Neutrophil extracellular traps: a potential therapeutic target in MPO-ANCA associated vasculitis? Front Immunol. 2021 Mar 15. 12:635188.Published 2021. DOI:10.3389/fimmu.2021.635188
   Google Scholar
• Chen M, Jayne DRW, Zhao MH. Complement in ANCA-associated vasculitis: mechanisms and implications for management. Nat Rev Nephrol. 2017;13(6):359–367.
   PubMed Web of Science ®Google Scholar
• Huang YM, Wang H, Wang C, et al. Promotion of hypercoagulability in antineutrophil cytoplasmic antibody-associated vasculitis by C5a-induced tissue factor-expressing microparticles and neutrophil extracellular traps. Arthritis Rheumatol. 2015;67(10):2780–2790.
   PubMed Web of Science ®Google Scholar
• Morozumi S, Koike H, Tomita M, et al. Spatial distribution of nerve fiber pathology and vasculitis in microscopic polyangiitis-associated neuropathy. J Neuropathol Exp Neurol. 2011;70(5):340–348.
   PubMed Web of Science ®Google Scholar
• Dyck PJ, Conn DL, Okazaki H. Necrotizing angiopathic neuropathy. Three-dimensional morphology of fiber degeneration related to sites of occluded vessels. Mayo Clin Proc. 1972;47(7):461–475.
   PubMed Web of Science ®Google Scholar
• Nukada H, Dyck PJ. Microsphere embolization of nerve capillaries and fiber degeneration. Am J Pathol. 1984;115(2):275–287.
   PubMed Web of Science ®Google Scholar
• Sladky JT, Greenberg JH, Brown MJ. Regional perfusion in normal and ischemic rat sciatic nerves. Ann Neurol. 1985;17(2):191–195.
   PubMed Web of Science ®Google Scholar
• Nukada H, van Rij AM, Packer SG, et al. Pathology of acute and chronic ischaemic neuropathy in atherosclerotic peripheral vascular disease. Brain. 1996;119(Pt 5):1449–1460.
   PubMedGoogle Scholar
• Takahashi M, Koike H, Ikeda S, et al. Distinct pathogenesis in nonsystemic vasculitic neuropathy and microscopic polyangiitis. Neurol Neuroimmunol Neuroinflamm. 2017;4(6):e407.
   PubMed Web of Science ®Google Scholar
• Koike H, Furukawa S, Mouri N, et al. Early ultrastructural lesions of anti-neutrophil cytoplasmic antibody- versus complement-associated vasculitis [published online ahead of print, 2022 Jun 15]. Neuropathology. 2022. DOI:10.1111/neup.12821.
   PubMed Web of Science ®Google Scholar
• Fukami Y, Koike H, Iijima M, et al. Role of complement components in vasculitic neuropathy associated with systemic lupus erythematosus and rheumatoid arthritis. Muscle Nerve. 2022;66(2):175–182.
   PubMed Web of Science ®Google Scholar
• Mori K, Iijima M, Koike H, et al. The wide spectrum of clinical manifestations in Sjögren’s syndrome-associated neuropathy. Brain. 2005;128(Pt 11):2518–2534.
   PubMed Web of Science ®Google Scholar
• Riku Y, Ikenaka K, Koike H, et al. Cutaneous arteritis associated with peripheral neuropathy: two case reports. J Dermatol. 2014;41(3):266–267.
   PubMed Web of Science ®Google Scholar
• Guillevin L, Durand-Gasselin B, Cevallos R, et al. Microscopic polyangiitis: clinical and laboratory findings in eighty-five patients. Arthritis Rheum. 1999;42(3):421–430.
   PubMed Web of Science ®Google Scholar
• Guillevin L, Cohen P, Gayraud M, et al. Churg-strauss syndrome. Clinical study and long-term follow-up of 96 patients. Medicine (Baltimore). 1999;78(1):26–37.
   PubMed Web of Science ®Google Scholar
• Imboden JB. Involvement of the peripheral nervous system in polyarteritis nodosa and antineutrophil cytoplasmic antibodies-associated vasculitis. Rheum Dis Clin North Am. 2017;43(4):633–639.
   PubMed Web of Science ®Google Scholar
• Cattaneo L, Chierici E, Pavone L, et al. Peripheral neuropathy in Wegener’s granulomatosis, Churg-Strauss syndrome and microscopic polyangiitis. J Neurol Neurosurg Psychiatry. 2007;78(10):1119–1123.
   PubMed Web of Science ®Google Scholar
• Suppiah R, Hadden RD, Batra R, et al. Peripheral neuropathy in ANCA-associated vasculitis: outcomes from the European vasculitis study group trials. Rheumatology (Oxford). 2011;50(12):2214–2222.
   PubMed Web of Science ®Google Scholar
• Cacoub P, Delluc A, Saadoun D, et al. Anti-CD20 monoclonal antibody (rituximab) treatment for cryoglobulinemic vasculitis: where do we stand? Ann Rheum Dis. 2008;67(3):283–287.
   PubMed Web of Science ®Google Scholar
• De Vita S, Quartuccio L, Isola M, et al. A randomized controlled trial of rituximab for the treatment of severe cryoglobulinemic vasculitis. Arthritis Rheum. 2012;64(3):843–853.
   PubMed Web of Science ®Google Scholar
• Puéchal X, Said G, Hilliquin P, et al. Peripheral neuropathy with necrotizing vasculitis in rheumatoid arthritis. A clinicopathologic and prognostic study of thirty-two patients. Arthritis Rheum. 1995;38(11):1618–1629.
   PubMedGoogle Scholar
• Omdal R, Henriksen OA, Mellgren SI, et al. Peripheral neuropathy in systemic lupus erythematosus. Neurology. 1991;41(6):808–811.
   PubMed Web of Science ®Google Scholar
• Pyrpasopoulou A, Chatzimichailidou S, Aslanidis S. Vascular disease in systemic lupus erythematosus. Autoimmune Dis. 2012;2012:876456.
   PubMedGoogle Scholar
• Brito-Zerón P, Akasbi M, Bosch X, et al. Classification and characterisation of peripheral neuropathies in 102 patients with primary Sjögren’s syndrome. Clin Exp Rheumatol. 2013;31(1):103–110.
   PubMed Web of Science ®Google Scholar
• Said G, Lacroix C, Planté-Bordeneuve V, et al. Nerve granulomas and vasculitis in sarcoid peripheral neuropathy: a clinicopathological study of 11 patients. Brain. 2002;125(Pt 2):264–275.
   PubMed Web of Science ®Google Scholar
• Ferri C, La Civita L, Cirafisi C, et al. Peripheral neuropathy in mixed cryoglobulinemia: clinical and electrophysiologic investigations. J Rheumatol. 1992;19(6):889–895.
   PubMed Web of Science ®Google Scholar
• Collins MP, Periquet MI. Isolated vasculitis of the peripheral nervous system. Clin Exp Rheumatol. 2008;26(3 Suppl 49):S118–30.
   PubMed Web of Science ®Google Scholar
• Collins MP, Dyck PJB, Hadden RDM. Update on classification, epidemiology, clinical phenotype and imaging of the nonsystemic vasculitic neuropathies. Curr Opin Neurol. 2019;32(5):684–695.
   PubMed Web of Science ®Google Scholar
• Dyck PJ, Norell JE, Dyck PJ. Microvasculitis and ischemia in diabetic lumbosacral radiculoplexus neuropathy. Neurology. 1999;53(9):2113–2121.
   PubMed Web of Science ®Google Scholar
• Dyck PJ, Norell JE, Dyck PJ. Non-diabetic lumbosacral radiculoplexus neuropathy: natural history, outcome and comparison with the diabetic variety. Brain. 2001;124(Pt 6):1197–1207.
   PubMedGoogle Scholar
• Massie R, Mauermann ML, Staff NP, et al. Diabetic cervical radiculoplexus neuropathy: a distinct syndrome expanding the spectrum of diabetic radiculoplexus neuropathies. Brain. 2012;135(Pt 10):3074–3088.
   PubMedGoogle Scholar
• Staff NP, Engelstad J, Klein CJ, et al. Post-surgical inflammatory neuropathy. Brain. 2010;133(10):2866–2880.
   PubMedGoogle Scholar
• Nishi R, Koike H, Ohyama K, et al. Differential clinicopathologic features of EGPA-associated neuropathy with and without ANCA. Neurology. 2020;94(16):e1726–37.
   PubMed Web of Science ®Google Scholar
• Hattori N, Mori K, Misu K, et al. Mortality and morbidity in peripheral neuropathy associated Churg-Strauss syndrome and microscopic polyangiitis. J Rheumatol. 2002;29(7):1408–1414.
   PubMed Web of Science ®Google Scholar
• Hattori N, Ichimura M, Nagamatsu M, et al. Clinicopathological features of Churg-Strauss syndrome-associated neuropathy. Brain. 1999;122(Pt 3):427–439.
   PubMedGoogle Scholar
• Garces-Sanchez M, Laughlin RS, Dyck PJ, et al. Painless diabetic motor neuropathy: a variant of diabetic lumbosacral radiculoplexus Neuropathy? Ann Neurol. 2011;69(6):1043–1054.
   PubMed Web of Science ®Google Scholar
• Agadi JB, Raghav G, Mahadevan A, et al. Usefulness of superficial peroneal nerve/peroneus brevis muscle biopsy in the diagnosis of vasculitic neuropathy. J Clin Neurosci. 2012;19(10):1392–1396.
   PubMed Web of Science ®Google Scholar
• Collins MP, Mendell JR, Periquet MI, et al. Superficial peroneal nerve/peroneus brevis muscle biopsy in vasculitic neuropathy. Neurology. 2000;55(5):636–643.
   PubMed Web of Science ®Google Scholar
• de Groot K, Schmidt DK, Arlt AC, et al. Standardized neurologic evaluations of 128 patients with Wegener granulomatosis. Arch Neurol. 2001;58(8):1215–1221.
   PubMedGoogle Scholar
• Stone JH. Wegener’s granulomatosis etanercept trial research group. Limited versus severe Wegener’s granulomatosis: baseline data on patients in the Wegener’s granulomatosis etanercept trial. Arthritis Rheum. 2003;48(8):2299–2309.
   PubMedGoogle Scholar
• Sinico RA, Di Toma L, Maggiore U, et al. Prevalence and clinical significance of antineutrophil cytoplasmic antibodies in Churg-Strauss syndrome. Arthritis Rheum. 2005;52(9):2926–2935.
   PubMed Web of Science ®Google Scholar
• Sablé-Fourtassou R, Cohen P, Mahr A, et al. Antineutrophil cytoplasmic antibodies and the Churg-Strauss syndrome. Ann Intern Med. 2005;143(9):632–638.
   PubMed Web of Science ®Google Scholar
• Healy B, Bibby S, Steele R, et al. Antineutrophil cytoplasmic autoantibodies and myeloperoxidase autoantibodies in clinical expression of Churg-Strauss syndrome. J Allergy Clin Immunol. 2013;131(2):571–6.e66.
   PubMed Web of Science ®Google Scholar
• Comarmond C, Pagnoux C, Khellaf M, et al. Eosinophilic granulomatosis with polyangiitis (Churg-Strauss): clinical characteristics and long-term followup of the 383 patients enrolled in the French Vasculitis Study Group cohort. Arthritis Rheum. 2013;65(1):270–281.
   PubMed Web of Science ®Google Scholar
• McCluskey L, Feinberg D, Cantor C, et al. “Pseudo-conduction block” in vasculitic neuropathy. Muscle Nerve. 1999;22:1361–1366.
   PubMed Web of Science ®Google Scholar
• Gorson KC. Vasculitic neuropathies: an update. Neurologist. 2007;13(1):12–19.
   PubMed Web of Science ®Google Scholar
• Dyck PJ, Windebank AJ. Diabetic and nondiabetic lumbosacral radiculoplexus neuropathies: new insights into pathophysiology and treatment. Muscle Nerve. 2002;25(4):477–491.
   PubMed Web of Science ®Google Scholar
• Grayson PC, Ponte C, Suppiah R, et al. American College of Rheumatology/European Alliance of Associations for Rheumatology classification criteria for eosinophilic granulomatosis with polyangiitis. Ann Rheum Dis. 2022;81(3):309–314.
   PubMed Web of Science ®Google Scholar
• Koike H, Nishi R, Furukawa S, et al. In vivo visualization of eosinophil secretion in eosinophilic granulomatosis with polyangiitis: an ultrastructural study. Allergol Int. 2022;71(3):373–382.
   PubMed Web of Science ®Google Scholar
• Guillevin L, Pagnoux C, Karras A, et al. Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis. N Engl J Med. 2014;371(19):1771–1780.
   PubMed Web of Science ®Google Scholar
• Specks U, Merkel PA, Seo P, et al. Efficacy of remission-induction regimens for ANCA-associated vasculitis. N Engl J Med. 2013;369(5):417–427.
   PubMed Web of Science ®Google Scholar
• Mukhtyar C, Guillevin L, Cid MC, et al. EULAR recommendations for the management of primary small and medium vessel vasculitis. Ann Rheum Dis. 2009;68(3):310–317.
   PubMed Web of Science ®Google Scholar
• Walton EW. Giant-cell granuloma of the respiratory tract (Wegener’s granulomatosis). Br Med J. 1958;2(5091):265–270.
   PubMed Web of Science ®Google Scholar
• Wallace ZS, Miloslavsky EM. Management of ANCA associated vasculitis. BMJ. 2020; 368:m421. doi:10.1136/bmj.m421
   PubMedGoogle Scholar
• Yates M, Watts RA, Bajema IM, et al. EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitis. Ann Rheum Dis. 2016;75(9):1583–1594. [published correction appears in Ann Rheum Dis. 2017 Aug;76(8):1480][published correction appears in Ann Rheum Dis. 2022 Jun;81(6):e109]
   PubMed Web of Science ®Google Scholar
• Walsh M, Merkel PA, Peh CA, et al. Plasma exchange and glucocorticoids in severe ANCA-associated vasculitis. N Engl J Med. 2020;382(7):622–631.
   PubMed Web of Science ®Google Scholar
• Hiemstra TF, Walsh M, Mahr A, et al. Mycophenolate mofetil vs azathioprine for remission maintenance in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized controlled trial. JAMA. 2010;304(21):2381–2388.
   PubMed Web of Science ®Google Scholar
• Tieu J, Smith R, Basu N, et al. Rituximab for maintenance of remission in ANCA-associated vasculitis: expert consensus guidelines. Rheumatology (Oxford). 2020;59(4):e24–e32.
   PubMed Web of Science ®Google Scholar
• Huugen D, van Esch A, Xiao H, et al. Inhibition of complement factor C5 protects against anti-myeloperoxidase antibody-mediated glomerulonephritis in mice. Kidney Int. 2007;71(7):646–654.
   PubMed Web of Science ®Google Scholar
• Moiseev S, Lee JM, Zykova A, et al. The alternative complement pathway in ANCA-associated vasculitis: further evidence and a meta-analysis. Clin Exp Immunol. 2020;202(3):394–402.
   PubMed Web of Science ®Google Scholar
• Jayne DRW, Merkel PA, Schall TJ, et al. Avacopan for the treatment of ANCA-associated vasculitis. N Engl J Med. 2021;384(7):599–609.
   PubMed Web of Science ®Google Scholar
• Koike H, Nishi R, Yagi S, et al. A review of anti-IL-5 therapies for eosinophilic granulomatosis with polyangiitis. Adv Ther. 2022;1–16. DOI:10.1007/s12325-022-02307-x
   Web of Science ®Google Scholar
• Wechsler ME, Akuthota P, Jayne D, et al. Mepolizumab or placebo for eosinophilic granulomatosis with polyangiitis. N Engl J Med. 2017;376(20):1921–1932.
   PubMed Web of Science ®Google Scholar
• Bettiol A, Urban ML, Dagna L, et al. Mepolizumab for eosinophilic granulomatosis with polyangiitis: a European multicenter observational study. Arthritis Rheumatol. 2022;74(2):295–306.
   PubMed Web of Science ®Google Scholar
• Crickx E, Machelart I, Lazaro E, et al. Intravenous immunoglobulin as an immunomodulating agent in antineutrophil cytoplasmic antibody-associated vasculitides: a French nationwide study of ninety-two patients. Arthritis Rheumatol. 2016;68(3):702–712.
   PubMed Web of Science ®Google Scholar
• Koike H, Akiyama K, Saito T, et al. Intravenous immunoglobulin for chronic residual peripheral neuropathy in eosinophilic granulomatosis with polyangiitis (Churg-Strauss syndrome): a multicenter, double-blind trial. J Neurol. 2015;262(3):752–759.
   PubMed Web of Science ®Google Scholar
• Ikeda T, Komatsu T, Yokoyama K, et al. Early add-on administration of mepolizumab and intravenous immunoglobulin effective in treating eosinophilic granulomatosis with polyangiitis. J Dermatol. 2021;48(4):529–532.
   PubMed Web of Science ®Google Scholar
• De Vita S, Soldano F, Isola M, et al. Preliminary classification criteria for the cryoglobulinaemic vasculitis. Ann Rheum Dis. 2011;70(7):1183–1190.
   PubMed Web of Science ®Google Scholar
• Sneller MC, Hu Z, Langford CA. A randomized controlled trial of rituximab following failure of antiviral therapy for hepatitis C virus-associated cryoglobulinemic vasculitis. Arthritis Rheum. 2012;64(3):835–842.
   PubMed Web of Science ®Google Scholar
• Terrier B, Krastinova E, Marie I, et al. Management of noninfectious mixed cryoglobulinemia vasculitis: data from 242 cases included in the CryoVas survey. Blood. 2012;119(25):5996–6004.
   PubMed Web of Science ®Google Scholar
• Terrier B, Launay D, Kaplanski G, et al. Safety and efficacy of rituximab in nonviral cryoglobulinemia vasculitis: data from the French Autoimmunity and Rituximab registry. Arthritis Care Res (Hoboken). 2010;62(12):1787–1795.
   PubMed Web of Science ®Google Scholar
• Audemard-Verger A, Pillebout E, Guillevin L, et al. IgA vasculitis (Henoch-Shönlein purpura) in adults: diagnostic and therapeutic aspects. Autoimmun Rev. 2015;14(7):579–585.
   PubMed Web of Science ®Google Scholar
• Thiel J, Rizzi M, Engesser M, et al. B cell repopulation kinetics after rituximab treatment in ANCA-associated vasculitides compared to rheumatoid arthritis, and connective tissue diseases: a longitudinal observational study on 120 patients. Arthritis Res Ther. 2017;19(1):101.
   PubMedGoogle Scholar
• Aringer M, Costenbader K, Daikh D, et al. European League Against Rheumatism/American college of rheumatology classification criteria for systemic lupus erythematosus. Arthritis Rheumatol. 2019;71(9):1400–1412.
   PubMed Web of Science ®Google Scholar
• Bertsias GK, Ioannidis JP, Aringer M, et al. EULAR recommendations for the management of systemic lupus erythematosus with neuropsychiatric manifestations: report of a task force of the EULAR standing committee for clinical affairs. Ann Rheum Dis. 2010;69(12):2074–2082. doi:10.1136/ard.2010.130476
   Google Scholar
• Constantin A, Năstase D, Tulbă D, et al. Immunosuppressive therapy of systemic lupus erythematosus associated peripheral neuropathy: a systematic review. Lupus. 2020;29(12):1509–1519.
   PubMed Web of Science ®Google Scholar
• Navarra SV, Guzmán RM, Gallacher AE, et al. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial. Lancet. 2011;377(9767):721–731.
   PubMed Web of Science ®Google Scholar
• Furie R, Petri M, Zamani O, et al. A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. Arthritis Rheum. 2011;63(12):3918–3930.
   PubMed Web of Science ®Google Scholar
• Flores-Chávez A, Kostov B, Solans R, et al. Severe, life-threatening phenotype of primary Sjögren’s syndrome: clinical characterisation and outcomes in 1580 patients (GEAS-SS Registry). Clin Exp Rheumatol. 2018;36(Suppl 112(3):):121–129.
   PubMed Web of Science ®Google Scholar
• Terrier B, Lacroix C, Guillevin L, et al. Diagnostic and prognostic relevance of neuromuscular biopsy in primary Sjögren’s syndrome-related neuropathy. Arthritis Rheum. 2007;57(8):1520–1529.
   PubMedGoogle Scholar
• Mekinian A, Ravaud P, Hatron PY, et al. Efficacy of rituximab in primary Sjogren’s syndrome with peripheral nervous system involvement: results from the AIR registry. Ann Rheum Dis. 2012;71(1):84–87.
   PubMed Web of Science ®Google Scholar
• Rist S, Sellam J, Hachulla E, et al. Experience of intravenous immunoglobulin therapy in neuropathy associated with primary Sjögren’s syndrome: a national multicentric retrospective study. Arthritis Care Res (Hoboken). 2011;63(9):1339–1344.
   PubMed Web of Science ®Google Scholar
• Chiche L, Bataille S, Kaplanski G, et al. The place of immunotherapy in the management of HCV-induced vasculitis: an update. Clin Dev Immunol. 2012;2012:315167.
   PubMedGoogle Scholar
• Ferri C, Cacoub P, Mazzaro C, et al. Treatment with rituximab in patients with mixed cryoglobulinemia syndrome: results of multicenter cohort study and review of the literature. Autoimmun Rev. 2011;11(1):48–55.
   PubMed Web of Science ®Google Scholar
• Davies L, Spies JM, Pollard JD, et al. Vasculitis confined to peripheral nerves. Brain. 1996;119(Pt 5):1441–1448.
   PubMedGoogle Scholar
• Collins MP, Periquet MI, Mendell JR, et al. Nonsystemic vasculitic neuropathy: insights from a clinical cohort. Neurology. 2003;61(5):623–630.
   PubMed Web of Science ®Google Scholar
• Levy Y, Uziel Y, Zandman G, et al. Response of vasculitic peripheral neuropathy to intravenous immunoglobulin. Ann N Y Acad Sci. 2005;1051:779–786.
   PubMed Web of Science ®Google Scholar
• Stone JH, Merkel PA, Spiera R, et al. Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med. 2010;363(3):221–232.
   PubMed Web of Science ®Google Scholar
• National institute of health. U.S National Library of medicine; the assessment of prednisone in remission trial (TAPIR) -patient centric approach (TAPIR). 2013. [cited 2022 Dec]. Available from: https://clinicaltrials.gov/ct2/show/NCT01933724
   Google Scholar
• de Groot K, Harper L, Jayne DR, et al. Pulse versus daily oral cyclophosphamide for induction of remission in antineutrophil cytoplasmic antibody — associated vasculitis: a randomized. Ann Intern Med. 2009;150(10):670–680.
   PubMed Web of Science ®Google Scholar
• Jayne D, Rasmussen N, Andrassy K, et al. A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies. N Engl J Med. 2003;349:36–44.
   PubMed Web of Science ®Google Scholar
• Pagnoux C, Mahr A, Hamidou MA, et al. French Vasculitis Study Group. Azathioprine or methotrexate maintenance for ANCA-associated vasculitis. N Engl J Med. 2008;359:2790–2803.
   PubMed Web of Science ®Google Scholar
• De Groot K, Rasmussen N, Bacon PA, et al. Randomized trial of cyclophosphamide versus methotrexate for induction of remission in early systemic antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum. 2005;52:2461–2469.
   PubMed Web of Science ®Google Scholar
• Jones RB, Hiemstra TF, Ballarin J, et al. European Vasculitis Study Group (EUVAS). Mycophenolate mofetil versus cyclophosphamide for remission induction in ANCA-associated vasculitis: a randomised, non-inferiority trial. Ann Rheum Dis. 2019;78:399–405.
   PubMed Web of Science ®Google Scholar
• Jones RB, Tervaert JW, Hauser T, et al. European Vasculitis Study Group. Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis. N Engl J Med. 2010;363:211–220.
   PubMed Web of Science ®Google Scholar
• Charles P, Terrier B, É Perrodeau, et al. French Vasculitis Study Group. Comparison of individually tailored versus fixed-schedule rituximab regimen to maintain ANCA-associated vasculitis remission: results of a multicentre, randomised controlled, phase III trial (MAINRITSAN2). Ann Rheum Dis. 2018;77(8):1143–1149.
   PubMed Web of Science ®Google Scholar
• Smith R, Jayne D, Merkel PA. A randomized, controlled trial of rituximab versus azathioprine after induction of remission with rituximab for patients with ANCA-associated vasculitis and relapsing disease [abstract 806]. Arthritis Rheumatol. 2019;71(suppl):10.
   Google Scholar
• Charles P, Perrodeau E, Samson M, et al. Long-term rituximab use to maintain remission of antineutrophil cytoplasmic antibody-associated vasculitis: a randomized trial. Ann Intern Med. 2020;173:179–187.
   PubMed Web of Science ®Google Scholar
• Terrier BPG, de Moreuil C, Bonnotte B, et al. Rituximab versus conventional therapeutic strategy for remission induction in eosinophilic granulomatosis with polyangiitis: a double-blind, randomized, controlled trial [abstract]. Arthritis Rheum. 2021;73((Suppl 10)).
   Google Scholar
• Furuta S, Nakagomi D, Kobayashi Y, et al. Effect of reduced-dose vs high-dose glucocorticoids added to rituximab on remission induction in ANCA-associated vasculitis: a randomized clinical trial. JAMA. 2021;325(21):2178–2187.
   PubMed Web of Science ®Google Scholar
• Jayne DRW, Bruchfeld AN, Harper L, et al. Randomized trial of C5a receptor inhibitor avacopan in ANCA-associated vasculitis. J Am Soc Nephrol. 2017;28:2756–2767.
   PubMed Web of Science ®Google Scholar
• Jayne D, Blockmans D, Luqmani R, et al. Efficacy and safety of belimumab and azathioprine for maintenance of remission in anti-neutrophil cytoplasmic antibody-associated vasculitis: a randomized controlled study. Arthritis Rheumatol. 2019;71:952–963.
   PubMed Web of Science ®Google Scholar
• Limper AH, Knox KS, Sarosi GA, et al. An official American Thoracic Society statement: treatment of fungal infections in adult pulmonary and critical care patients. Am J Respir Crit Care Med. 2011;183(1):96–128.
   PubMed Web of Science ®Google Scholar
• Buckley L, Guyatt G, Fink HA, et al. American College of Rheumatology guideline for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Rheumatol. 2017;69(8):1521–1537.
   PubMed Web of Science ®Google Scholar